Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I totally agree Barwick. RNS tomorrow/Thursday maybe?
And I’d say more news to come NST and soon.
Our Paris office @vennlifesciences has signed a contract with a new client
@Oxfordbio
With the Paris office rationalisation completed it is now on a significant growth and profit trajectory, with MANY more deals to follow.
As someone said yesterday, at least they are selling now before they get their hands on any new shares that they would get from any divi/ spin off.
And, TBH, if they keep the price down till the 6th of next month then I can put even more in next years Isa allowance. :)
Not everyone, DDB.
I ain't sellin' Jack. :)
SR84 - naive I'm afraid. not for profit just means they don't pay surplus out to investors et al. Doesn't mean they don't generate surplus - they need to to sustain the business. They will pay the going rate for anything / everything to run and develop their business. That includes using the best data management and statistics services for their studies i.e. ORPH
CF of Open Orphan, does nothing for free.
Risk of sounding very naive here... I’m going to ask a silly question!
Oxford Bio are a non-profit organisation. Would that mean that our services would be offered on the cheap, or would we just be swallowing up any “profits” sat in their bank?
Just trying to gauge whether this is a vanity RNS, great PR and exposure, or if this is going to add great revenue streams going forward.
Quick scan of their site and it looks like there are 10 pieces of pipe in that pipeline!!!!
I would think they're down to around 20m shares by now, (judging only by how fast they went from 40m to 30m).
Invesco may well sell into any rise but at least they'll be selling out faster and sooner.
Any idea how many more do the morons (sorry Invesco) have to shift?
First in class pipeline - nice, cause what do pipelines mean? Prizes!!
TIDMORPH
RNS Number : 5449R
Open Orphan PLC
09 March 2021
9 March 2021
Open Orphan plc
("Open Orphan" or the "Company")
New contract win with Oxford BioTherapeutics
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its subsidiary Venn Life Sciences ("Venn") has been awarded a contract for a study with Oxford BioTherapeutics, a clinical stage oncology company with a pipeline of immune-oncology and antibody-drug conjugate-based therapies.
This is a phase I, open-label, dose finding study which will be used to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of OBT076, a CD205-directed antibody-drug conjugate, in recurrent and/or metastatic CD205-positive solid tumours and in women with CD205-positive HER2-negative metastatic breast cancer.
For this study, the Venn Paris team will deliver high-quality data management and statistics services. Venn's team in Paris are highly regarded in the field as one of the leading providers in this area which is a perfect complement to the Company's London offering. The study is due to start immediately.
Cathal Friel, Executive Chairman, Open Orphan, commented: "We are delighted to be in a position to announce another contract win for the Paris team. This deal further demonstrates Open Orphan's ability to execute on its significant pipeline of contracts with important pharmaceutical businesses.
"Oxford BioTherapeutics is a clinical stage oncology company with a pipeline of first-in-class therapies aiming to fulfil major unmet patient needs by targeting difficult-to-treat cancers. The Venn team are looking forward to assisting with the study and providing the preliminary data required to advance this breast cancer trial."
Dr Rahim Fandi, MD, PhD Oxford BioTherapeutics CMO commented: "We are delighted to work with Venn and are sure that Oxford BioTherapeutics will benefit from their expertise."
For further information please contact: